Pila Pharma AB (FRA:5KC) Total Liabilities: €0.15 Mil (As of Dec. 2025)


FRA:5KC Pila Pharma AB FRA:5KC
49 GF Score
Price €0.10
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Pila Pharma AB Total Liabilities?

Pila Pharma AB FRA:5KC -3.24% 49 Total Liabilities is €0.15 Mil as of Dec. 2025. GuruFocus rates FRA:5KC with a GF Score™ of 49/100 and a GF Value™ of €0.15. The stock has 3 warning signs investors should review.

Pila Pharma AB's Total Liabilities for the quarter that ended in Dec. 2025 was €0.15 Mil.

Pila Pharma AB's quarterly Total Liabilities increased from Dec. 2024 (€0.08 Mil) to Jun. 2025 (€0.21 Mil) but then declined from Jun. 2025 (€0.21 Mil) to Dec. 2025 (€0.15 Mil).

Pila Pharma AB's annual Total Liabilities declined from Dec. 2023 (€0.16 Mil) to Dec. 2024 (€0.08 Mil) but then increased from Dec. 2024 (€0.08 Mil) to Dec. 2025 (€0.15 Mil).


Pila Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Pila Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pila Pharma AB Total Liabilities Chart

Pila Pharma AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 0.15 0.12 0.16 0.08 0.15

Pila Pharma AB Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.17 0.08 0.21 0.15
FRA:5KC
49GF Score
Pila Pharma AB FRA:5KC
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pila Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pila Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.49-1.346
=0.14

Pila Pharma AB's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1.49-1.346
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.15 Mil mean?
Pila Pharma AB (FRA:5KC) has a Total Liabilities of €0.15 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pila Pharma AB and its competitors.
Is Pila Pharma AB's Total Liabilities too high?
Pila Pharma AB's current Total Liabilities is €0.15 Mil. Overall, Pila Pharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's Total Liabilities compare to VRTX and REGN?
Pila Pharma AB's Total Liabilities of €0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pila Pharma AB and its competitors. Pila Pharma AB's current Total Liabilities is €0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current Total Liabilities of €0.15 Mil. The stock's GF Value™ is €0.15, compared to a current price of €0.10 — trading 30.3% below its estimated fair value. The current Total Liabilities is €0.15 Mil. Pila Pharma AB's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current Total Liabilities is €0.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?

Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued. The current stock price of €0.10 is trading 30.3% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:5KC:

  • Total Liabilities: €0.15 Mil
  • GF Value™: €0.15 vs. price of €0.10 (30.3% below fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pila Pharma AB Business Description

Other Exchanges PILA:Sweden
Address Norra Vallgatan 72, Malmo, SWE, 211 21
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
49GF Score

Get the complete analysis for FRA:5KC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.15
GF Value